Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Intellipharmaceutics International Inc's Business Segments
Intellipharmaceutics International Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
-
Regions Reported
1
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/IPCIF/segments
https://api.csimarket.com/api/v1/companies/IPCIF/geographic
https://api.csimarket.com/api/v1/companies/IPCIF/exposure
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Annual Results
Revenue Share by Country -
- Canadas28.9%
Revenue by Geographic Country -
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| Canadas | $ 0 | 28.9% |
Description of Intellipharmaceutics International Inc
Intellipharmaceutics International Inc. is a pharmaceutical company that specializes in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company is based in Toronto, Ontario, Canada, and was founded in 1998.
Intellipharmaceutics is known for its proprietary Hypermatrix technology, which enables the development of controlled-release drug delivery systems. These systems provide a sustained release of medication, offering advantages such as improved patient compliance, reduced side effects, and enhanced therapeutic efficacy.
The company's product pipeline includes both branded and generic drugs. They focus on therapeutic areas such as neurology, cardiovascular, and diabetes. Some of their branded products target conditions like attention deficit hyperactivity disorder (ADHD) and depression.
Intellipharmaceutics has a number of products that are currently in various stages of development, including those seeking U.S. Food and Drug Administration (FDA) approval. Their lead product candidate is Rexista, an abuse-deterrent formulation of oxycodone hydrochloride, which is intended to be used for the treatment of moderate to severe pain.
In addition to their proprietary drug delivery technology, Intellipharmaceutics also holds a number of patents for drug formulations and manufacturing processes. These patents provide the company with a competitive advantage and allow them to protect their unique innovations.
The company has a strong research and development team consisting of scientists, engineers, and pharmacists. They collaborate with academic institutions, research organizations, and other pharmaceutical companies for the advancement of drug development and delivery technologies.
Intellipharmaceutics has manufacturing facilities that comply with good manufacturing practices (GMP) guidelines, ensuring the production of high-quality medications. They have the capability to produce both clinical and commercial scale products.
In terms of intellectual property, Intellipharmaceutics has a robust portfolio of patents and patent applications, providing them with market exclusivity for their products. They actively pursue strategic partnerships, licensing agreements, and collaborations to further enhance their portfolio, expand their market presence, and drive revenue growth.
As a publicly traded company, Intellipharmaceutics is listed on the NASDAQ exchange under the ticker symbol IPCI. They are dedicated to creating shareholder value by delivering innovative drug products to market and generating sustainable revenue streams.
Overall, Intellipharmaceutics International Inc. is a pharmaceutical company that is focused on the research, development, and manufacturing of controlled-release oral solid dosage drugs. With their proprietary technology, diverse product pipeline, and commitment to innovation, the company aims to make a significant impact within the pharmaceutical industry.
Intellipharmaceutics is known for its proprietary Hypermatrix technology, which enables the development of controlled-release drug delivery systems. These systems provide a sustained release of medication, offering advantages such as improved patient compliance, reduced side effects, and enhanced therapeutic efficacy.
The company's product pipeline includes both branded and generic drugs. They focus on therapeutic areas such as neurology, cardiovascular, and diabetes. Some of their branded products target conditions like attention deficit hyperactivity disorder (ADHD) and depression.
Intellipharmaceutics has a number of products that are currently in various stages of development, including those seeking U.S. Food and Drug Administration (FDA) approval. Their lead product candidate is Rexista, an abuse-deterrent formulation of oxycodone hydrochloride, which is intended to be used for the treatment of moderate to severe pain.
In addition to their proprietary drug delivery technology, Intellipharmaceutics also holds a number of patents for drug formulations and manufacturing processes. These patents provide the company with a competitive advantage and allow them to protect their unique innovations.
The company has a strong research and development team consisting of scientists, engineers, and pharmacists. They collaborate with academic institutions, research organizations, and other pharmaceutical companies for the advancement of drug development and delivery technologies.
Intellipharmaceutics has manufacturing facilities that comply with good manufacturing practices (GMP) guidelines, ensuring the production of high-quality medications. They have the capability to produce both clinical and commercial scale products.
In terms of intellectual property, Intellipharmaceutics has a robust portfolio of patents and patent applications, providing them with market exclusivity for their products. They actively pursue strategic partnerships, licensing agreements, and collaborations to further enhance their portfolio, expand their market presence, and drive revenue growth.
As a publicly traded company, Intellipharmaceutics is listed on the NASDAQ exchange under the ticker symbol IPCI. They are dedicated to creating shareholder value by delivering innovative drug products to market and generating sustainable revenue streams.
Overall, Intellipharmaceutics International Inc. is a pharmaceutical company that is focused on the research, development, and manufacturing of controlled-release oral solid dosage drugs. With their proprietary technology, diverse product pipeline, and commitment to innovation, the company aims to make a significant impact within the pharmaceutical industry.
Intellipharmaceutics International Inc. is a pharmaceutical company primarily focused on developing and manufacturing complex and controlled-release generic and branded drug products. The company employs its proprietary technologies aimed at enhancing the bioavailability and therapeutic potential of its drug formulations. Here’s an extensive overview of the segments, products, and services offered by Intellipharmaceutics:
1. Segments
Intellipharmaceutics operates primarily in the pharmaceutical segment, specializing in:
- Generic Pharmaceuticals: The company develops generic versions of existing medications, focusing on drugs with complex delivery systems that can be difficult to replicate.
- Branded Pharmaceuticals: Intellipharmaceutics also works on proprietary brand formulations, potentially leading to new market entries that offer improved therapeutic options.
Product Offerings
The product offerings from Intellipharmaceutics include:
A. Controlled-Release Formulations
Intellipharmaceutics is renowned for its development of controlled-release drug formulations, designed to release active ingredients in a controlled manner over a period. Key examples include:
- IntelliSelect™ Technology: A platform for optimizing drug delivery and release profiles, adapting to the specific pharmacokinetic needs of different medications.
- IntelliSorb™ Technology: A technology aimed at enhancing the solubility and absorption of poorly water-soluble drugs, thus improving therapeutic efficacy.
B. Complex Generic Products
The company focuses on harder-to-manufacture generic products that may include:
- Extended-Release Dosage Forms: Generic alternatives to branded extended-release medications that provide therapeutic benefits over time without the need for frequent dosing.
- Abuse-Deterrent Formulations: Addressing the opioid crisis, Intellipharmaceutics has been involved in the development of formulations that are difficult to misuse or abuse, targeting safer medication practices.
C. Branded Prescription Drugs
The company also develops branded product candidates which may include:
- Opioid Analgesics: Leveraging their technologies to create formulations that mitigate the risks associated with opioid misuse while maintaining effective pain management.
- Psychiatric and Neurological Drugs: Developing formulations targeted at mental health disorders, potentially offering better treatment adherence through controlled-release mechanisms.
Services Offered
A. Product Development Services
Intellipharmaceutics provides extensive services in product development that may involve:
- Formulation Development: Tailoring drug formulations based on client specifications with a focus on enhancing bioavailability, stability, and patient compliance.
- Analytical Services: Offering rigorous testing of formulations to ensure they meet regulatory standards and specifications.
B. Regulatory Affairs
The company has a strong expertise in navigating the regulatory landscape, which includes:
- Submission to Regulatory Authorities: Preparing and submitting Investigational New Drug (IND) applications, New Drug Applications (NDA), Abbreviated New Drug Applications (ANDAs), and other necessary documentation.
- Compliance Support: Providing ongoing support to ensure that the products meet the required legal and safety standards over their lifecycle.
C. Partnership and Licensing Opportunities
Intellipharmaceutics often seeks strategic partnerships and licensing agreements, including:
- Out-Licensing: Licensing their proprietary technologies to other pharmaceutical companies for product development and commercialization.
- Collaborative Development: Engaging in partnerships with other firms for co-development projects, which might leverage Intellipharmaceutics technologies.
In summary, Intellipharmaceutics International Inc. offers a comprehensive array of pharmaceutical products and services, focusing significantly on complex drug formulations and innovative delivery technologies. Their dedication to addressing key issues such as pain management and controlled release aims to meet both market demands and improve patient outcomes.
1. Segments
Intellipharmaceutics operates primarily in the pharmaceutical segment, specializing in:
- Generic Pharmaceuticals: The company develops generic versions of existing medications, focusing on drugs with complex delivery systems that can be difficult to replicate.
- Branded Pharmaceuticals: Intellipharmaceutics also works on proprietary brand formulations, potentially leading to new market entries that offer improved therapeutic options.
Product Offerings
The product offerings from Intellipharmaceutics include:
A. Controlled-Release Formulations
Intellipharmaceutics is renowned for its development of controlled-release drug formulations, designed to release active ingredients in a controlled manner over a period. Key examples include:
- IntelliSelect™ Technology: A platform for optimizing drug delivery and release profiles, adapting to the specific pharmacokinetic needs of different medications.
- IntelliSorb™ Technology: A technology aimed at enhancing the solubility and absorption of poorly water-soluble drugs, thus improving therapeutic efficacy.
B. Complex Generic Products
The company focuses on harder-to-manufacture generic products that may include:
- Extended-Release Dosage Forms: Generic alternatives to branded extended-release medications that provide therapeutic benefits over time without the need for frequent dosing.
- Abuse-Deterrent Formulations: Addressing the opioid crisis, Intellipharmaceutics has been involved in the development of formulations that are difficult to misuse or abuse, targeting safer medication practices.
C. Branded Prescription Drugs
The company also develops branded product candidates which may include:
- Opioid Analgesics: Leveraging their technologies to create formulations that mitigate the risks associated with opioid misuse while maintaining effective pain management.
- Psychiatric and Neurological Drugs: Developing formulations targeted at mental health disorders, potentially offering better treatment adherence through controlled-release mechanisms.
Services Offered
A. Product Development Services
Intellipharmaceutics provides extensive services in product development that may involve:
- Formulation Development: Tailoring drug formulations based on client specifications with a focus on enhancing bioavailability, stability, and patient compliance.
- Analytical Services: Offering rigorous testing of formulations to ensure they meet regulatory standards and specifications.
B. Regulatory Affairs
The company has a strong expertise in navigating the regulatory landscape, which includes:
- Submission to Regulatory Authorities: Preparing and submitting Investigational New Drug (IND) applications, New Drug Applications (NDA), Abbreviated New Drug Applications (ANDAs), and other necessary documentation.
- Compliance Support: Providing ongoing support to ensure that the products meet the required legal and safety standards over their lifecycle.
C. Partnership and Licensing Opportunities
Intellipharmaceutics often seeks strategic partnerships and licensing agreements, including:
- Out-Licensing: Licensing their proprietary technologies to other pharmaceutical companies for product development and commercialization.
- Collaborative Development: Engaging in partnerships with other firms for co-development projects, which might leverage Intellipharmaceutics technologies.
In summary, Intellipharmaceutics International Inc. offers a comprehensive array of pharmaceutical products and services, focusing significantly on complex drug formulations and innovative delivery technologies. Their dedication to addressing key issues such as pain management and controlled release aims to meet both market demands and improve patient outcomes.